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Abstract
Background The objective of our study was to assess
whether TG2A levels in the healthy childhood population
can be predictive of subclinical CD.
Methods A total of 4442 children (median age, 6.0 years)
participating in a population-based prospective cohort
study were screened on serum TG2A. Those with positive
TG2A (C7 U/ml; n = 60, 1.4%) were invited for clinical
evaluation (median age, 9.0 years). Medical history,
physical examination, serum TG2A, and IgA-endomysium
(EMA) were assessed, as well as HLA DQ 2.2/2.5/8 typing.
Patients with positive serologies and genetic risk types
underwent duodenal biopsies. TG2A levels at the time of
biopsy were compared with the degree of enteropathy.
Results Fifty-one TG2A-positive children were included in
the follow-up: 31 (60.8%) children had CD, ten (19.6%)
did not have CD, and ten (19.6%) were considered
potential CD cases because of inconclusive serologies.
Duodenal biopsies were performed in 26/31 children. CD
with Marsh 3a/b enteropathy was observed in 75% (15/20)
of children having TG2A levels C10ULN at 6 years of age,
as well as in 75% (6/8) of children having a positive TG2A
\10 ULN (OR 1.00; 95% CI 0.15–6.64). CD cases had a
lower BMI SDS (mean -0.49, SD 0.92) than children
without CD (mean 0.47, SD 1.37; p = 0.02). No differ-
ences were observed in gastrointestinal symptoms.
Conclusions Serum TG2A screening at 6 years of age in
the healthy childhood population has a positive predictive
value of 61% to detect subclinical CD. We did not find a
positive correlation between serum TG2A levels and the
degree of enteropathy.
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Introduction
Celiac disease (CD) is one of the most common, but largely
underdiagnosed chronic diseases in childhood, and asso-
ciated with excess morbidity and mortality [1]. The
prevalence of CD is 0.5–3% and increasing over time
[2–5]. Despite increased awareness among physicians,
active case-finding and screening strategies [6–9], the
majority of CD patients still remain unrecognized in
childhood. Diagnosis is difficult as recent insights have
shown CD can be present in asymptomatic children that do
have a positive serology as well as enteropathy [10].
CD can be characterized by the presence of serum IgA
against transglutaminase type 2 (TG2A), IgA against
endomysium (EMA), genetic carriership for HLA DQ2.2,
DQ2.5 and/or DQ8, and a gluten induced enteropathy [11],
which is graded according to the Marsh-Oberhuber criteria
[12–14]. Serum TG2A and EMA positivities have sensitivi-
ties and specificities of[90% for detection of small intestinal
enteropathy [15]. Screening of healthy populations fre-
quently detects seropositive subjects without symptoms and
with mild enteropathy (i.e., subclinical CD), or seropositive
subjects with normal small bowel mucosa (i.e., potential
CD). Thus, serology testing is only the first step in the
diagnosis [6]. Nevertheless, several studies have shown that
high TG2A levels (C10 times upper limit normal of the test;
ULN) have a high specificity for severe enteropathy (Marsh
3) in symptomatic patients [16–18]. Therefore, the ESP-
GHAN guideline recommends that biopsies may be omitted
when TG2A levels C10 ULN in symptomatic patients. It is
still recommended to evaluate biopsies in asymptomatic or
screening-identified individuals, irrespective of TG2A levels
[19], although some studies argue the need in subclinical and
screening-detected patients with TG2A levels C10 ULN
values [20]. Recently, one study found that TG2A levels
correlate with the severity of mucosal lesions in both
asymptomatic and symptomatic children [21]. Still, studies
validating the correlation between TG2A levels and the
degree of enteropathy in subclinical CD are scarce.
Therefore, the primary aim of this study was to study the
positive predictive value of TG2A screening to detect
subclinical CD in the healthy childhood population. A
second aim was to study whether serum TG2A levels in
subclinical CD correlate with the degree of enteropathy.
Materials and methods
Design and screening strategy
This study was embedded within the Generation R study, a
prospective population-based cohort study from fetal life
until young adulthood, described in detail previously
[22, 23]. Children were born between April 2002 and
January 2006 in Rotterdam, The Netherlands. At the age of
6 years, 6690 children visited the research center. During
this visit, serum samples were collected from 4593 (69%)
children and subsequently stored over a time period of
2.5 years [22]. In 2013, after the inclusion of the whole
cohort was completed and children were 9 years old, these
samples were thawed and analyzed for TG2A levels.
Children and parents were not aware of TG2A determi-
nation. We excluded 20 children in whom total IgA con-
centrations were below the detection limit, possibly
indicating IgA deficiency. Finally, 4442 children provided
data on TG2A levels at 6 years of age [24, 25]. Between
November and December 2013, when children were
9 years old, parents of 60 children were informed about a
positive TG2A screening result at 6 years of age, and
invited for diagnostic follow-up. Of these, eight children
were lost to follow-up and one child was diagnosed with
CD prior to the initial serology screening at 5 years of age,
and therefore excluded. Of the remaining 51 children, two
were on a gluten-free diet (GFD), and had been diagnosed
with CD prior to the follow-up (between 6 and 9 years of
age). Therefore, these children were excluded from clinical
retesting (but not from the final analyses). In total, 49
children received diagnostic follow-up within 3 months
after initial notification of the elevated TG2A level at
9 years of age (January to April 2014). None of them
consumed a low- or gluten-free diet (GFD).
Written informed consent was obtained from all par-
ticipants. Approval for the study was obtained from the
Medical Ethical Committee of Erasmus MC, University
Medical Centre Rotterdam, The Netherlands.
Screening on serum TG2A
TG2A serum levels were measured using a fluorescence
enzyme immunoassay (EliA Celikey IgA, Phadia Immu-
noCAP 250, Phadia AB, Uppsala, Sweden). The intra- and
interassay coefficient of variation (CV) was below 10 and
15%, respectively. Sera with a TG2A level of 7 U/ml or
higher were considered to be positive per the manufac-
turer’s instructions. We further subdivided positive TG2A
levels into two categories on the basis of below or above
the 10 upper limit normal (ULN) of the test kit ([70 U/ml)
[19, 24, 25].
Diagnostic follow-up
Of 51 children included, two were diagnosed with CD
between 6 and 9 years of age, and one child received fol-
low-up elsewhere (Fig. 1). To assess whether clinical
symptoms were different between the CD groups
(Table 1), these three children were excluded from
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analyses (but not from the final analyses). From the
remaining 48 children visiting the Sophia Children’s
Hospital at the median age of 9.9 years, a standardized
medical and family history was taken by a pediatric gas-
troenterologist. The presence of gastrointestinal complaints
was assessed systematically after parents were informed
about the TG2A positivity at 6 years of age. Information on
gluten intake was assessed by diet questions recorded at
6 years of age prior to TG2A screening, and at the moment
of follow-up at 9 years of age, by asking whether their
child had been on a low- or GFD. If not, the child was
considered to be exposed to a normal amount of gluten.
Height and weight were measured without shoes and heavy
clothing, and body mass index (BMI; kg/m2) was calcu-
lated. Age- and sex-adjusted standard deviation scores
(SDS) were obtained using Dutch reference growth curves
[26]. Prior data on height and weight as recorded in the
community health centers were included. A delay in linear
growth over time was defined as decrease of [0.5 SD
height-for-age relative to the normal SD line. The second
TG2A test at 9 years of age was performed using the same
fluorescence enzyme immunoassay (exact same kit). In
addition, anti-endomysial antibody (anti-EMA) levels were
measured, and children were genotyped for HLA DQ2.2,
DQ2.5, and/or DQ8. Serological criteria for recommending
an upper gastrointestinal (GI) endoscopy are summarized
in Fig. 1. All GI endoscopies were performed by two
experienced pediatric gastroenterologists (MG or JCE)
between March and December 2014. Mucosal biopsies
were taken from both the proximal (including the bulb) and
distal (2nd or 3rd) part of the duodenum as recommended
[27–29]. Enteropathy was graded according to the Marsh-
Oberhuber criteria [12, 13], which can vary from intraep-
ithelial lymphocytosis (IEL; C30 lymphocytes/100 ente-
rocytes; grade 1) to more extensive lesions including crypt
hyperplasia (grade 2), and various degrees of villous atro-
phy (grade 3a partial; grade 3b subtotal, grade 3c total).
Enteropathy was defined as having Marsh II or greater [19].
HLA DQ2/DQ8– TG2A - EMA- (n=3)
HLA DQ2/DQ8+ TG2A - (0 U/ml) EMA- (n=6) 
HLA DQ2/DQ8- TG2A <3ULN EMA- (n=1)
(n=10)
HLA DQ2 DQ8 + TG2A >10 ULN EMA+ (n= 20)
HLA DQ2 DQ8 + TG2A >10 ULN EMA- (n= 0)
(n=20) 
Retesng serology 9-yr (n=49)
Intesnal biopsy performed (n=26/31)
Follow-up
n=10
Marsh grade 1
n=3 
(of whom TG2A > 10 ULN n=3)
Marsh grade 2-3
n=23
(of whom TG2A > 10 ULN n=16)
TG2A and HLA DQ2/DQ8 posive children (n=60, TG2A >7 U/ml) 
Follow-up elsewhere 
(1 diagnosis, based on 2x TG2A >10 ULN) and clinical symptoms
Exclusion: n=1 CD diagnosis at 5 yrs of age (biopsy conﬁrmed marsh 3a/b)
Lost (n=8) (4 no contact, 4 no consent FU) 
HLA DQ2/DQ8+ TG2A - EMA+ (n=2)
HLA DQ2/DQ8+ TG2A - (>5<7 U/ml) EMA- (n=2)
HLA DQ2/DQ8 + TG2A <3 ULN EMA+ (n=2)
HLA DQ2/DQ8 + TG2A <3 ULN EMA- (n=1)
(n=7)
No celiac disease
n=10
Subclinical celiac disease 
n=31
Erasmus MC Sophia Children’s Hospital (n=48)
HLA DQ2/DQ8 + TG2A (>3<10 ULN) EMA+(n=11) 
HLA DQ2/DQ8+ TG2A (>3<10 ULN) EMA- (n=0) 
(n=11)
no consent 
GI endoscopy (n=5) 
of whom TG2A >10 ULN 
(n=3)
n=7
10/51 = 19.6%
10/51 = 19.6%
31/51 = 60.8%
Screening on TG2A levels in cohort  (n=4,442 children; median age 6.0 years)
Inclusion: n=2 CD diagnosis at 6 and 9 yrs of age (1 biopsy conﬁrmed, marsh 3a/b)    
No symptoms, no GFD (n=8)
Abdominal bloang, low gluten containing diet, (n=1)
Lost n=1
Fig. 1 Outcome of screening for anti-tissue transglutaminase anti-
bodies (TG2A) in a population-based prospective cohort study. Sixty
children had a positive TG2A test result at 6 years of age; 31/51
(60.8%) children were considered to have CD, 10/51 (19.6%) children
needed follow-up, and 10/51 (19.6%) children did not have CD
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Endomysial antibodies
Endomysial antibodies (EmA) of IgA isotype were
determined by indirect immunofluorescence using com-
mercial monkey esophagus slides, according to the man-
ufacturer’s instructions (Inova Diagnostics, San Diego,
CA) (S1).
Genotyping of HLA DQ2.2, 2.5, and DQ8
Presence of CD-associated HLA-DQ haplotypes DQ2.2
(DQA1*02/DQB1*02), DQ2.5 (DQA1*05/DQB1*02) and
DQ8 (DQA1*0301/DQB1*0302) was determined by
EUROArray, according to the manufacturer’s instructions
(Euroimmun AG, Lu¨beck, Germany) (S1) [30].
Table 1 Characteristics according to celiac disease diagnosis
Characteristics Diagnosis
No CD (n = 10) Potential CD (n = 10) Definitive CD (n = 28) p valueb
Age at outpatient center (median; range; years) 10.6 (9.9–11.4) 9.1 (8.4–10.3) 9.8 (8.6–11.2) <0.01
Female gender (n; %) 8 (80%) 7 (70%) 19 (68%) 0.48
Medical history
Asymptomatic* 1 (10%) 3 (30%) 9 (32%) 0.17
No GI symptoms 1 (10%) 3 (30%) 10 (36%) 0.12
Abdominal pain (n; %) 7 (70%) 5 (50%) 16 (57%) 0.88
Constipation (n;%) 4 (40%) 1 (10%) 12 (43%) 0.88
Diarrhea (n; %) 4 (40%) 0 (0%) 6 (21%) 0.25
Nausea (n; %) 3 (30%) 1 (10%) 8 (29%) 0.93
Vomiting (n;%) 2 (20%) 0 (0%) 1 (4%) 0.10
[2 gastrointestinal symptoms (n; %) 6 (60%) 1 (10%) 11 (39%) 0.26
[3 gastrointestinal symptoms (n; %) 3 (30%) 0 (0%) 9 (32%) 0.90
Fatigue (n; %) 4 (40%) 1 (10%) 3 (11%) 0.04
GP visit for abdominal complaints (n; %) 2 (20%) 1 (10%) 0 (0%) 0.02
Family with CD (n; %)
1st degree 0 (0%) 2 (20%) 1 (4%) 0.48
2nd degree 0 (0%) 1 (10%) 4 (14%)
3rd degree 1 (10%) 0 (0%) 1 (4%)
Physical examination
Delayed linear growth curve 0–9 yearsa (n; %) 1 (10%) 1 (10%) 3 (11%) 0.47
Missing data (n; %) 1 (10%) 2 (20%) 8 (29%)
Height 9 years (median; range; cm) 147.2 (132.2–158.2) 135.0 (131.0–153.5) 138.6 (105.0–164.2) 0.32
Weight 9 years (median; range; kg) 36.8 (25.9–69.8) 28.6 (27.1–50.4) 29.3 (19.2–61.6) 0.04
BMI (median; range; kg/m2) 17.5 (14.4–27.9) 15.5 (15.1–21.4) 15.4 (12.8–22.8) 0.04
Height for age SDS (mean; SD) -0.45 (1.30) -0.09 (0.78) -0.24 (1.05) 0.61
Weight for age SDS (mean; SD) 0.06 (1.68) -0.20 (0.78) -0.45 (0.99) 0.26
BMI for age SDS (mean; SD) 0.47 (1.37) -0.11 (0.66) 20.49 (0.92) 0.02
Bold values indicate significant differences (p\0.05) between the CD groups
CD celiac disease, GI gastrointestinal, GP general practitioner, BMI body mass index, SDS standard deviation score adjusted for sex and age,
TG2A tissue transglutaminase type 2 antibody (IgA), ULN upper limit normal. Values represent means (SD’s), medians (range), or numbers
(percentages)
a Delayed linear growth was defined as: C-0.75 to 1.5 SDS decrease over time from 0 to 9 years of age
b p value reflects differences between biopsy proven (definitive CD) and potential CD group versus ‘No CD = reference’ group (Mann–Whitney
U tests were used for non-normally distributed variables, and v2 tests were used to test for differences in proportions between groups)
*‘Asymptomatic’ refers to no GI symptoms, nor anorexia, fatigue, or irritability. None of the children was diagnosed with an autoimmune
disease, including diabetes mellitus 1, or autoimmune thyroid disease. Thirty-one children were classified as definitive CD cases, but only 28
were included in the analyses, because two children were diagnosed at an earlier age because of symptoms, and one child was diagnosed in
another hospital (diagnosis was based on 29 TG2A[10 ULN in accordance with clinical symptoms), thus assessment of medical histories and
physical examination may be different from the 28 asymptomatic children included in the analyses
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Statistical analysis
Chi-square tests were used to test whether gastro-intestinal
complaints were different between the children with and
without final CD diagnosis. The variables ‘more than two
gastrointestinal complaints’ and ‘more than three gas-
trointestinal complaints’ were calculated by taking the sum
of the following complaints: abdominal pain (y/n), con-
stipation (y/n), diarrhea (y/n), nausea (y/n), and vomiting
(y/n), resulting in two dichotomous variables. Non-para-
metric Mann–Whitney U tests were used to test for dif-
ferences in non-normally distributed variables, including
median age, height, weight, and BMI between children
with and without CD diagnosis. Chi-square tests were used
to test whether clinical complaints and the degree of
enteropathy were related to the TG2A categories. Binary
logistic regression analyses were performed to test whether
TG2A levels were related to CD diagnosis (CD versus no
CD, and potential CD versus no CD) and enteropathy
(Marsh 3 versus Marsh 0, 1, or 2).
Results
Subject characteristics
Of 4442 screened children (median age, 6.0 years), 60
(1.4%) had increased TG2A levels (C7 U/ml), of whom 31
children had TG2A levels above 10 ULN ([70 U/ml). Of
60 children, eight were lost to follow-up, and one child was
diagnosed with CD at 5 years of age (prior to the initial
serology screening) and therefore excluded from analyses.
Two children (4%) had received a CD diagnosis in the
period preceding retesting (between 6 and 9 years of age)
and consumed a gluten-free diet (GFD). Here, CD was
detected based on gastrointestinal symptoms by routine
clinical care in the Netherlands, of whom one diagnosis
was confirmed by biopsy (Marsh 3a/3b) (Fig. 1).
Outcome of follow-up
Of 48 children who were retested in the Sophia Children’s
Hospital, 31 (65%) were positive for TG2A and EMA,
carried HLA DQ2.2, DQ2.5, or DQ8, and were advised to
undergo gastrointestinal endoscopy. Of these, 20 had
TG2A levels C10 ULN (Fig. 1). Of 26 children who
underwent GI endoscopy, 20 had Marsh grade 3 [(3a
n = 13), 3b (n = 7)]; three children had Marsh grade 2;
and three children had Marsh grade 1. Of 23 children with
Marsh grade 2–3 lesions, 16 (70%) had TG2A levels C10
ULN. All three children with Marsh grade 1 lesions had
TG2A levels C10 ULN and were advised to continue on a
gluten-containing diet, and to consider a second serology
and/or intestinal biopsy when clinical complaints compat-
ible with CD occur. A total of ten children were HLA
DQ2.2, DQ2.5, and DQ8 negative, or carried the genetic
risk type but lacked EMA and TG2A positivity, and were
therefore considered not to have CD. The second serology
was not conclusive in seven children: they carried the
genetic risk type, but had TG2A concentrations\3 ULN,
or TG2A levels were negative in accordance with a posi-
tive EMA, whereas the initial screening TG2A test result at
6 years of age was positive. Furthermore, these children
mentioned gastrointestinal complaints (abdominal pain),
and had a first-degree family history of CD (in contrast to
the ten children who were considered not to have CD).
Hence, these children were advised to be serologically
retested in 6–12 months. During the period of follow-up
(January 2014 to April 2017), none of the ten children
received a CD diagnosis; only one child occasionally
mentioned complaints of abdominal bloating, and was on a
low-gluten-containing diet (but not a gluten-free diet). The
remaining children did not mention CD-associated symp-
toms while consuming a gluten-containing diet.
In total, 31 of 51 (60.8%) children were considered to
have CD, of whom two had developed symptomatic CD
within 3 years after the screening test was performed;
10/51 (19.6%) needed follow-up because of inconclusive
serology (n = 7) or negative intestinal biopsies (n = 3, of
whom all three had levels exceeding 10 ULN); and 10/51
(19.6%) were considered to not have CD (Fig. 1). Thus, the
positive predictive value of TG2A screening was 61%,
(95% CI 49–75), to detect subclinical CD and 81%, (95%
CI 70–91) to detect both potential and subclinical CD.
Clinical symptoms
All 48 children consumed a normal gluten-containing diet
at 6 years of age, as well as at the visit to the pediatric
gastroenterologist at 9–10 years. Of 28 CD cases who
provided data on medical history and physical examination
at 9 years of age, nine (32%) children were truly asymp-
tomatic relative to one (10%) of the children without CD
diagnosis (p = 0.17). Abdominal pain was reported most
frequently (57%), followed by constipation (43%), nausea
(29%), and diarrhea (21%), but no significant differences in
gastrointestinal symptoms were observed between children
with and without CD diagnosis (p = 0.12) (Table 1). In
addition, no significant differences were observed in the
presence of anorexia, irritability, food allergy, lactose
intolerance, eczema, and absenteeism from school between
children with and without CD diagnosis (data not shown),
nor in family history of CD (Table 1). However, CD cases
weighed less (median 29.3 kg; range, 19.2–61.6, p = 0.04)
than children who did not have CD (median 36.8 kg; range,
25.9–69.8). In addition, their BMI was lower (mean BMI
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SDS -0.49, SD 0.92, p = 0.04) compared to children
without CD (mean BMI SDS 0.47, SD 1.37) No significant
differences in height were observed between children with
and without CD diagnosis (p[ 0.32) (Table 1). Associa-
tions were not substantially different in children without
gastrointestinal symptoms [S2].
In addition, no significant differences in gastrointestinal
symptoms were observed between children who were
TG2A negative (\7 U/ml) and strongly positive (C10
ULN), but children having TG2A levels exceeding 10 ULN
weighed less (median 29.1 kg, range, 19.2–44.0) and had a
lower BMI (mean BMI SDS -0.51, SD 0.85), than chil-
dren who were TG2A negative (median 35.3 kg, range,
25.9–69.8 and SDS BMI 0.21, SD 1.16 resp.) [S3].
Development of CD over time according to CD
diagnosis
We observed a high variability in serum TG2A levels at 6
and 9 years of age (Fig. 2). Of 29 CD cases, 20 children
(69%) had high TG2A levels (C10 ULN) at 6 years of age,
which increased to a higher level in the majority (16/20) of
cases at 9 years of age. Of ten children who needed follow-
up at 9 years of age because of negative serologies, four
children (40%) had TG2A concentrations exceeding 10
ULN levels at 6 years of age. Of six children who carried
the genetic risk type, but did not have CD, one child had
TG2A levels exceeding 10 ULN at 6 years of age (Fig. 2).
Association between level of TG2A concentration,
CD diagnosis, and degree of enteropathy
A positive linear tendency was observed for TG2A levels
in predicting CD diagnosis: children having high TG2A
levels (C10 ULN) at 6 and 9 years of age were more fre-
quently diagnosed with CD than children having TG2A-
positive concentrations below\10 ULN (OR 7.7; 95% CI
2.2–27.4) and [OR 10.0 (1.07–93.4) resp.] [S4]. Second,
we observed that TG2A levels at 6 or 9 years of age were
not related to the presence of severe intestinal enteropathy
(Marsh 3) [S5] (Fig. 3).
Incidence of celiac disease in TG2A-negative cohort
At the child’s age of 9 years, parents were asked by
questionnaire whether their child had ever received a
doctors diagnosis of CD. Of 4382 TG2A-negative children
at 6 years of age, nine (0.2%) received a doctors diagnosis
of CD between 6 and 9 years of age.
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Fig. 2 Serum TG2A concentrations at 6 and 9 years of age according
to celiac disease diagnosis. Thin dotted line indicates clinical cutoff
for IgA-TG2A positivity (C7 U/ml). a TG2A concentrations between
6–9 years in CD group, bold line reflects n=14 CD cases who had
strong positive IgA-TG2A concentrations ([125 U/ml at 6 years of
age, and [128 U/ml at 9 years of age). b TG2A concentrations
between 6–9 years in potential CD group. c TG2A concentrations
between 6–9 years in children who lacked criteria for CD diagnosis.
Four children were excluded because of negative genetic risk type. In
addition, three children who received a CD diagnosis between 6 and 9
years of age were excluded from this figure
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Discussion
This population-based prospective cohort study shows that:
(1) Serum TG2A screening at 6 years of age in the healthy
childhood population has a positive predictive value of
61% to detect subclinical CD. (2) The level of serum
TG2A in subclinical CD is not predictive for the severity of
enteropathy.
Although we followed the ESPGHAN guideline for CD
diagnosis in the majority of asymptomatic children, the
PPV of TG2A screening may still have been influenced by
misclassification of the outcome. According to the Oslo
definitions [10], potential CD refers to children who are at
increased risk of developing CD as indicated by positive
serology, but with a normal small intestinal bowel mucosa.
In our study, 23 children were considered to have sub-
clinical CD on the basis of the combination of positive
TG2A and the presence of enteropathy. However, five CD
cases did not consent for GI endoscopy, thus we lacked
formal proof for diagnosis of CD. Still, three of them had
elevated levels[10 ULN, and they were all EmA and HLA
DQ2 or 8 positive, suggesting that enteropathy is highly
likely. Therefore, excluding these children would likely
result in underdiagnosis. Second, loss to follow-up might
have affected the precision of the PPV of TG2A screening.
If children who were lost to follow-up (n = 8) would not
have CD, then the initial PPV of screening on TG2A would
have been 31/59 (53%). In contrast, if all children who
were lost would be CD cases, then the PPV would have
been 39/59 (66%) Thus, the positive predictive value of
serum TG2A screening to detect subclinical CD in the
general childhood population would be maximally 66%.
In contrast with several other studies, we did not find a
positive association between serum TG2A levels and the
degree of enteropathy [16, 21, 31–33]. However, these
previous studies concerned children with gastrointestinal
symptoms that triggered CD testing, and contrast our cases
of subclinical CD, complicating a direct comparison
between studies. In fact, it has been shown that TG2A
levels are more strongly correlated with the severity of
intestinal lesions in symptomatic patients, than in asymp-
tomatic children [21]. Hence, the association between
TG2A levels and the degree of enteropathy might be dif-
ferentially influenced by the presence -or lack- of symp-
toms. In our study, the majority of children with high
TG2A levels mentioned gastrointestinal symptoms.
According to the ESPGHAN guideline, biopsies could
have been omitted in this group. However, on the basis of
the present study, it needs to be considered that children
with TG2A C10 ULN in most cases needed a biopsy to
confirm CD. Moreover, our results confirm that the pres-
ence and severity of gastrointestinal symptoms, such as
abdominal pain, are insufficient to discriminate subclinical
CD cases from healthy children [34]. The majority (90%)
of children who did not develop CD mentioned gastroin-
testinal symptoms as well, such as abdominal pain,
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constipation, diarrhea, nausea, or fatigue. Gastrointestinal
symptoms were also not related to the degree of
enteropathy, nor TG2A levels. Nonetheless, consistent with
our previous findings [25], subclinical children weighed
less than healthy children. Interestingly, the TEDDY study
demonstrated that the majority of subclinical children had
normal weight and height growth at age 4 [21], which may
suggest that the deviation in height and weight growth
becomes more prominent between 4 and 6 years of age,
and appears before gastrointestinal symptoms occur.
Hence, increased clinical vigilance focusing on weight
growth parameters, especially BMI [35], or systematic
growth monitoring in the general pediatric population,
might improve early detection of CD [36]. Nevertheless,
the effects of early diagnosis, and the benefit of treatment
with a gluten-free diet of subclinical patients, needs to be
further studied. In the short run, symptoms that may -or
may not- have been recognized upon the start of a GFD
may disappear, serving as a proof to parents [37], but
evidence in children is lacking. In addition, the benefits and
cost-effectiveness of screening in asymptomatic individu-
als remains controversial [38–40]. Introducing a screening
test in the general pediatric population with a positive
predictive value of 61% to diagnose a disease with lifelong
consequences (such as a gluten-free diet, regular health
care visits, screening for other diseases, screening and
investigating family members, fear of complications, and
economic burden from the gluten-free diet) may not be
reasonable. Therefore, it would be too premature to rec-
ommend screening in the general pediatric population.
Methodological considerations
The premise of the study was the identification of CD in
asymptomatic children. Three children in our study
developed symptoms following screening, thereby trig-
gering CD diagnosis in routine clinical practice. One of the
strengths of our study is that we used a prospective study
design, with a similar protocol for the diagnostic process
for all screened TG2A-positive children. Furthermore, all
screened TG2A-positive children were of the same age,
and analyzed 3 years later by the same laboratory and same
test kit. Because all participants were unaware of TG2A
determination, we were able to study the development of
TG2A levels over 3 years of time. Ten children with
negative TG2A did not have CD, despite TG2A positivity
at 6 years of age. Explanations for the contradictory test
results at 6 and 9 years may be that TG2A levels were
transiently high at 6 years, test results at 6 years were false
positive (i.e., 1-specificity), or gluten intake decreased over
time. Intriguingly, on top of the 1.4% of children with
positive TG2A levels at 6 years of age (of whom 61%
received a subclinical CD diagnosis), 0.2% of TG2A
negative children developed CD within 3 years after the
negative TG2A screening result at 6 years of age. The
median age of retesting was 9.9 years, with a range
between 8.4 and 11.4 years. This large age range is related
to the inclusion period of 2.5 years. Another strength of our
study is that TG2A measurements were performed in
combination with assessment of EMA, genetic risk types,
and biopsy specimens at the same time of second serology
assessment. Last, all biopsies were evaluated by expert
pathologists by using the Marsh–Oberhuber criteria to
classify the degree of enteropathy. Nevertheless, several
limitations should be taken into account as well. First of all,
five children in the CD group were considered to have
subclinical CD without biopsy results. Therefore, we did
not fully meet the ESPGHAN criteria for CD diagnosis.
However, three of them had levels exceeding 10 ULN, they
were all EMA positive, and carried the genetic risk type.
Hence, CD diagnosis is highly likely. Second, symptoms
were assessed only among those with TG2A positivity at
9 years of age, after parents were informed about the initial
screening TG2A status, which might have induced bias.
However, the presence of gastrointestinal symptoms was
evaluated systematically during routine clinical evaluation,
preceding second serological (TG2A) assessment, addi-
tional EMA assessment, genetic risk typing, and gastroin-
testinal endoscopies at 9 years of age. Hence, symptom
assessment was independent of the outcome, making bias
less likely. Furthermore, symptoms were assessed by one
experienced gastroenterologist minimizing inter-observer
bias. We did not specifically ask for the presence of joint
pains or neurological symptoms, but these complaints were
not reported on the general question ‘‘any complaints’’.
Hence, the occurrence of joint pains and neurological
symptoms seems unlikely.
Conclusions
Our results indicate that the majority of asymptomatic
6-year-old TG2A-positive children developed subclinical
CD within 3 years following screening. We did not find a
positive association between serum TG2A concentrations
and the degree of enteropathy. Thus, TG2A screening at
6 years of age could substantially advance CD diagnosis as
children with subclinical CD in our study only showed a
small deviation in height and weight, and lacked gas-
trointestinal symptoms.
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